Universidad Peruana Cayetano Heredia

Case-Control Study to Estimate the Association Between Tdap Vaccination During Pregnancy and Reduced Risk of Pertussis in Newborn Infants in Peru, 2019-2021

Mostrar el registro sencillo del ítem

dc.contributor.author Juscamayta López, Julio Eduardo
dc.contributor.author Valdivia, Faviola
dc.contributor.author Soto, María Pía
dc.contributor.author Horna, Helen
dc.contributor.author Pajuelo Travezaño, Monica Jhenny
dc.coverage.spatial Perú
dc.date.accessioned 2023-09-06T20:45:07Z
dc.date.available 2023-09-06T20:45:07Z
dc.date.issued 2023
dc.identifier.uri https://hdl.handle.net/20.500.12866/14050
dc.description.abstract BACKGROUND: Despite widespread vaccination, pertussis has re-emerged as a serious public health concern worldwide. Since 2017, Peru has experienced an increase in pertussis cases exhibiting a higher risk of severity and death in young infants. Thus, a dose of the tetanus, diphtheria, and acellular pertussis (Tdap) vaccine is recommended for pregnant women in the third trimester. Although evidence suggests the maternal Tdap vaccine is safe and effective, its association with a reduced risk of pertussis in developing countries remains poorly investigated. METHODS: We conducted a case-control study to evaluate the association between Tdap vaccination during pregnancy and reduction in the risk of pertussis among infants aged <2 months in Peru. Pertussis cases and controls treated in healthcare facilities nationwide between 2019 and 2021 and confirmed by real-time polymerase chain reaction were included. The controls were randomly selected from test-negative patients. Odds ratios (ORs) and vaccine effectiveness (VE) were calculated using a multiple logistic regression model and 1 - (OR) × 100%, respectively. RESULTS: Fifty cases and 150 controls were included in the analysis. The mothers of 4% of cases and 16.7% of controls received Tdap vaccination during pregnancy, resulting in an OR of 0.19 (95% confidence interval [CI], .04-.86) and VE of 81% (95% CI, 14%-96%) for preventing pertussis in infants. CONCLUSIONS: Peruvian infants <2 months old whose mothers received the Tdap vaccine in the third trimester of pregnancy had a significantly lower risk of pertussis. The Tdap vaccination is thus an effective intervention to reduce the burden of pertussis in at-risk populations. en_US
dc.description.sponsorship Este trabajo fue financiado por el Instituto Nacional de Salud del Perú y por FONDECYT/CIENCIACTIVA [beca EF033-235-2015]. es_PE
dc.language.iso eng
dc.publisher Oxford University Press
dc.relation.ispartofseries Open Forum Infectious Diseases
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Pertussis en_US
dc.subject Maternal immunization en_US
dc.subject Peru en_US
dc.subject Pregnancy en_US
dc.subject Tdap en_US
dc.subject.mesh Tos Ferina
dc.subject.mesh Inmunización
dc.subject.mesh Perú
dc.subject.mesh Embarazo
dc.subject.mesh Vacuna contra Difteria y Tétanos
dc.title Case-Control Study to Estimate the Association Between Tdap Vaccination During Pregnancy and Reduced Risk of Pertussis in Newborn Infants in Peru, 2019-2021 en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1093/ofid/ofad325
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.08
dc.relation.issn 2328-8957


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas